CN116535415A - 一种七元环吲哚萜类化合物及其制备方法和用途 - Google Patents
一种七元环吲哚萜类化合物及其制备方法和用途 Download PDFInfo
- Publication number
- CN116535415A CN116535415A CN202310019184.5A CN202310019184A CN116535415A CN 116535415 A CN116535415 A CN 116535415A CN 202310019184 A CN202310019184 A CN 202310019184A CN 116535415 A CN116535415 A CN 116535415A
- Authority
- CN
- China
- Prior art keywords
- preparation
- terpenoid
- membered ring
- indole
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 indole terpenoid Chemical class 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title claims abstract description 25
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 title claims abstract description 25
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 title claims abstract description 25
- 150000001875 compounds Chemical class 0.000 claims abstract description 37
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 24
- 238000012258 culturing Methods 0.000 claims abstract description 13
- 238000004440 column chromatography Methods 0.000 claims abstract description 11
- 239000000287 crude extract Substances 0.000 claims abstract description 9
- 238000000855 fermentation Methods 0.000 claims abstract description 8
- 230000004151 fermentation Effects 0.000 claims abstract description 8
- 238000004321 preservation Methods 0.000 claims abstract description 5
- 238000002791 soaking Methods 0.000 claims abstract description 3
- 238000010828 elution Methods 0.000 claims description 21
- 239000001963 growth medium Substances 0.000 claims description 17
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 12
- 241000209094 Oryza Species 0.000 claims description 10
- 235000007164 Oryza sativa Nutrition 0.000 claims description 10
- 235000009566 rice Nutrition 0.000 claims description 10
- 239000013535 sea water Substances 0.000 claims description 10
- 229920001817 Agar Polymers 0.000 claims description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 239000008272 agar Substances 0.000 claims description 9
- 241000222122 Candida albicans Species 0.000 claims description 7
- 229940095731 candida albicans Drugs 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 239000001888 Peptone Substances 0.000 claims description 6
- 108010080698 Peptones Proteins 0.000 claims description 6
- 244000061456 Solanum tuberosum Species 0.000 claims description 6
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 6
- 239000003480 eluent Substances 0.000 claims description 6
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 6
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 6
- 239000002609 medium Substances 0.000 claims description 6
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 6
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 6
- 235000019319 peptone Nutrition 0.000 claims description 6
- 239000003208 petroleum Substances 0.000 claims description 6
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- 241000222290 Cladosporium Species 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 238000009630 liquid culture Methods 0.000 claims description 5
- 238000004007 reversed phase HPLC Methods 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000000741 silica gel Substances 0.000 claims description 4
- 229910002027 silica gel Inorganic materials 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 239000003337 fertilizer Substances 0.000 claims description 3
- 239000002054 inoculum Substances 0.000 claims description 3
- 238000002386 leaching Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 235000002639 sodium chloride Nutrition 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 241000320442 Cladosporium sphaerospermum Species 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 4
- 150000003505 terpenes Chemical class 0.000 claims 2
- 238000002953 preparative HPLC Methods 0.000 abstract description 2
- 238000010898 silica gel chromatography Methods 0.000 abstract 1
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 230000000843 anti-fungal effect Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 241000233866 Fungi Species 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 239000005820 Prochloraz Substances 0.000 description 1
- 241000082085 Verticillium <Phyllachorales> Species 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002678 macrocyclic compounds Chemical class 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000003592 new natural product Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000238 one-dimensional nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- TVLSRXXIMLFWEO-UHFFFAOYSA-N prochloraz Chemical compound C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl TVLSRXXIMLFWEO-UHFFFAOYSA-N 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明公开了一种七元环吲哚萜类化合物及其制备方法和用途,特点是该化合物的结构式如Ⅰ所示,其制备方法步骤包括将保藏号为CCTCC NO:M2014098的海洋球孢枝孢菌通过发酵培养来获取七元环吲哚萜类化合物的发酵物,然后将发酵物用乙酸乙酯浸泡提取得粗浸膏,在此基础上将该粗浸膏经正相硅胶柱层析,反向中压柱层析和反相半制备高效液相色谱分离纯化得到,优点是该七元环吲哚萜类具有抗白色念珠球菌的作用,可以用于开发预防和治疗由白色念珠球菌所引起的人体上呼吸道真菌感染的药物。
Description
技术领域
本发明涉及一种七元环吲哚萜类化合物,尤其是涉及一种从海洋真菌中提取的七元环吲哚萜类化合物及其制备方法和用途。
背景技术
吲哚萜类化合物是一类天然产物,它们都拥有一个共同的结构骨架,由一个环二萜与吲哚部分连接而成。这类化合物通常是于真菌中分离出来的,基于大环的大小不同以及环上的取代基不同,这些化合物具有很大的结构多样性。自1975年首次分离以来,吲哚萜类化合物因其强大而多样的生物活性而受到人们的极大关注。吲哚萜类化合物已被证明具有抗病毒、抗炎、抗菌、抗癌活性。
本发明人在对一株海洋真菌在大米培养基发酵下的乙酸乙酯提取物的化学调查中,发现了一个抗念珠球菌的新天然产物。目前尚未见该化合物的化学结构及抗念珠球菌的报道,因此市场上也尚未见有与此相关的药物。
发明内容
本发明所要解决的技术问题是提供一种对白色念珠菌具有抑制作用的七元环吲哚二萜类化合物及其制备方法和用途。
本发明解决上述技术问题所采用的技术方案为:
1、一种七元环吲哚萜类化合物,该类化合物的结构式如(I)所示;
2、一种七元环吲哚萜类化合物的制备方法,包括如下步骤:
(1)发酵生产
将保藏号为CCTCC NO:M2014098的球孢枝孢菌(CladosporiumsphaerospermumYS3-1-5)在PDA培养基的平板上划线,于28℃培养箱中培养活化7天后,挑取单菌落接种于PDB液体培养基中,于温度28℃、180rpm/min的转速下置于摇床上培养增菌,培养3天后收集种子液,然后将种子液按体积百分比10%的接种量接种到大米固体培养基中,于温度28℃培养30天,获得发酵物;
(2)浸膏提取
在步骤(1)得到的发酵物加入等量乙酸乙酯,反复萃取3次,随后对乙酸乙酯浸提液减压蒸干后获得粗浸膏;
(3)化合物的分离制备
将步骤(2)得到的粗浸膏首先用体积比为1:1的二氯甲烷和甲醇混合溶剂溶解后,加200-300目硅胶拌样,进行正相中压柱层析,采用体积比为(100:1)~(0:1)的石油醚-乙酸乙酯溶液为洗脱剂进行梯度洗脱,收集洗脱流分,按流分极性由小到大排列,合并得到6个组分;将收集的第2个组分进行反相中压柱层析梯度洗脱,采用体积百分比为25-100%的乙腈-水为洗脱剂,收集洗脱流分,按流分极性由大到小排列,合并得到38个组分;将得到的第8个组分采用乙腈与水按体积比34:66的比例混合的溶液为流动相,经半制备反相高效液相色谱分离纯化,获得化合物,其结构如(I)所示
进一步,步骤(1)中所述的大米培养基的配制方法如下:将90g大米、25g海盐溶于110mL海水中配制而成。
进一步,步骤(1)中所述的PDB液体培养基的配制方法如下:马铃薯200克、葡萄糖20克、琼脂20克、蛋白胨5克、磷酸二氢钾3克、硫酸镁1.5克溶于1000ml海水中配制而成;所述的PDA固体培养基的配制方法如下:马铃薯200克、葡萄糖20克、琼脂20克、蛋白胨5克、磷酸二氢钾3克、硫酸镁1.5克、琼脂粉18克溶于1000ml海水中配制而成。
进一步,步骤(3)所述的石油醚-乙酸乙酯溶液的洗脱梯度体积比依次为100:1、50:1、20:1、10:1、5:1、2:1、1:1和0:1。
进一步,步骤(3)中所述的反相中压柱层析梯度洗脱中乙腈体积百分比从25~100%,洗脱时间200min。
进一步,步骤(3)中所述的半制备反相高效液相色谱的化合物分离制备的流速为2.0mL/min。
3、上述七元环吲哚萜类化合物在制备白色念珠球菌和细胞株抑制剂方面的用途。
与现有技术相比,本发明的优点在于:本发明分离出一种七元环吲哚萜类化合物,通过微生物发酵培养来获取吲哚萜类的发酵物,然后通过将发酵物用乙酸乙酯浸泡提取,得粗浸膏,然后将该粗浸膏经中压正向硅胶柱层析,中压反向柱层析,及反相半制备高效液相色谱分离纯化得到,此外通过抗真菌活性的筛选,发现该化合物具有有效的抗白色念珠球菌活性与对细胞株具有有效的抑制作用,可用于抑制由白色念珠球菌引起的相关人体上呼吸道真菌感染的药物开发方面的用途。
上述球孢枝孢菌YS3-1-5(Cladosporium sphaerospermum YS3-1-5),于2014年3月21日保藏于中国典型培养物保藏中心,保藏编号为CCTCC No:M2014098,保藏地址为中国.武汉.武汉大学。
附图说明
图1为本发明化合物的核磁共振氢谱;
图2为本发明化合物的核磁共振碳谱
图3为本发明化合物的核磁共振DEPT-135谱;
图4为本发明化合物的核磁共振COSY谱;
图5为本发明化合物的核磁共振HSQC谱;
图6为本发明化合物的核磁共振HSQC谱;
图7为本发明化合物的核磁共振NOESY谱;
图8为本发明化合物的ECD绝对构型拟合曲线图1;
图9为本发明化合物的ECD绝对构型拟合曲线图2。
具体实施方式
以下结合实施例对本发明作进一步详细描述。
实施例1
一种七元环吲哚萜类化合物的结构式如(I)所示:
实施例2
如实施例1结构式(I)所示的吲哚萜类化合物的制备方法,具体包括如下步骤:
(1)发酵生产
将保藏号为CCTCC NO:M2014098的球孢枝孢菌(CladosporiumsphaerospermumYS3-1-5)在PDA固体培养基的平板上划线,于28℃培养箱中培养活化7天后,挑取单菌落接种于PDB液体培养基中,于温度28℃、180rpm/min的转速下置于摇床上培养增菌,培养3天后收集种子液,然后将种子液按体积比10%的接种量接种到大米培养基中,于温度28℃培养30天,获得发酵物,其中大米培养基的配制方法如下:将90g大米、25g海盐溶于110mL海水中配制而成;PDB液体培养基的配制方法如下:马铃薯200克、葡萄糖20克、琼脂20克、蛋白胨5克、磷酸二氢钾3克、硫酸镁1.5克溶于1000ml海水中配制而成;PDA固体培养基的配制方法如下:马铃薯200克、葡萄糖20克、琼脂20克、蛋白胨5克、磷酸二氢钾3克、硫酸镁1.5克、琼脂粉18克溶于1000ml海水中配制而成;
(2)浸膏提取
在步骤(1)得到的发酵物加入等量乙酸乙酯,反复浸泡3次,随后对乙酸乙酯浸提液减压蒸干后,获得粗浸膏;
(3)化合物的分离制备
首先用体积比为1:1的二氯甲烷和甲醇混合溶剂溶解后,加200-300目硅胶拌样,进行正相中压柱层析,采用体积比为(100:1)~(0:1)的石油醚-乙酸乙酯溶液(石油醚-乙酸乙酯溶液的洗脱梯度体积比依次为100:1、50:1、20:1、10:1、5:1、2:1、1:1和0:1)为洗脱剂进行梯度洗脱,收集洗脱流分,按流分极性由小到大排列,合并得到6个组分;将收集的第2个组分进行反相中压柱层析梯度洗脱,采用体积百分比为25-100%的乙腈-水为洗脱剂,收集洗脱流分,按流分极性由大到小排列,合并得到38个组分;将得到的第8个组分采用乙腈与水按体积比34:66的比例混合的溶液为流动相,经半制备反相高效液相色谱分离纯化获得化合物,其结构如(I)所示:
实施例3
化合物的结构鉴定及核磁信号归属
本发明化合物Ⅰ为白色粉末,正离子模式下的高分辨质谱(HR-ESI-MS)给出其准分子离子峰m/z 536.3376[M+H]+。结合13C NMR谱确定其分子式为C33H45NO5,通过对化合物I的1H-1H偶合常数和NOESY数据的分析,见图1至图7。确定3,4,9,12与18,20的相对构型,绝对构型通过NMR进行模拟计算,最后用ECD模拟计算数据与实际ECD数据验证一致,见图8和9。因此化合物I的绝对构型归属为3S,4R,9S,12S,18R,20S。
该化合物的1H和13C NMR谱数据见表1:
表1.化合物I的1D NMR数据(DMSO-d6,δin ppm,J in Hz)
注1:s—单重峰、d—二重峰、t—三重峰、q—四重峰、m—多重峰;
注2:1H在600MHz NMR获得;13C在150MHz NMR获得。
实施例4
实施例1所述吲哚萜类化合物抗真菌活性及应用
(1)实验样品
被测样品溶液的配制:测试样品为上述实施例1中分离纯化的化合物Ⅰ纯品,精密称取适量样品,用DMSO配制成所需浓度的溶液供测试抗真菌活性。该实验使用的指示菌为白色念珠球菌(ATCC10231)。
(2)实验方法
牛津杯法抗真菌测试方法:将100μL的孢子悬浮液均匀涂在PDA板上,在板中央放置牛津杯。牛津杯中分别加入100μL的不同浓度的化合物溶液,浓度为128μg/mL、64μg/mL、32μg/mL、16μg/mL、8μg/mL、4μg/mL、2μg/mL。以DMSO为阴性对照,同时以相同浓度的咪鲜胺作阳性对照。在28℃下培养5d后观察真菌生长情况,每个处理设4个培养板,整个实验重复3次。
(3)实验结果
牛津杯法抗真菌测试中,化合物Ⅰ对白色念珠球菌(ATCC10231)的MIC被确定为64μg/mL。
上述说明并非对本发明的限制,本发明也并不限于上述举例。本技术领域的普通技术人员在本发明的实质范围内,做出的变化、改型、添加或替换,也应属于本发明的保护范围。
Claims (8)
1.一种七元环吲哚萜类化合物,其特征在于该吲哚萜类化合物的结构式如(I)所示;
2.一种权利要求1所述的七元环吲哚萜类化合物的制备方法,其特征在于包括如下步骤:
(1)发酵生产
将保藏号为CCTCC NO:M2014098的球孢枝孢菌(Cladosporium sphaerospermum
YS3-1-5)在PDA固体培养基的平板上划线,于28℃培养箱中培养活化7天后,挑取单菌落接种于PDB液体培养基中,于温度28℃、180rpm/min的转速下置于摇床上培养増菌,培养3天后收集种子液,然后将种子液按体积比10%的接种量接种到大米固体培养基中,于温度28℃培养30天,获得发酵物;
(2)浸膏提取
在步骤(1)得到的发酵物加入等量乙酸乙酯,反复浸泡3次,随后对乙酸乙酯浸提液减压蒸干后,获得粗浸膏;
(3)化合物的分离制备
将步骤(2)得到的粗浸膏首先用体积比为1:1的二氯甲烷和甲醇混合溶剂溶解后,加200-300目硅胶拌样,进行正相中压柱层析,采用体积比为(100:1)~(0:1)的石油醚-乙酸乙酯溶液为洗脱剂进行梯度洗脱,收集洗脱流分,按馏分极性由小到大排列,合并得到6个组分;将收集的第2个组分进行反相中压柱层析梯度洗脱,采用体积比为25-100%的乙腈-水为洗脱剂,收集洗脱流分,按馏分极性由大到小排列,合并得到38个组分;将得到的第8个组分采用乙腈与水按体积比34:66的比例混合的溶液为流动相,经半制备反相高效液相色谱分离纯化,获得化合物,其结构如(I)所示:
3.根据权利要求2所述的一种七元环吲哚萜类化合物的制备方法,其特征在于步骤(1)中所述的大米培养基的配制方法如下:将90g大米、25g海盐溶于110mL海水中配制而成。
4.根据权利要求2所述的一种七元环吲哚萜类化合物的制备方法,其特征在于步骤(1)中所述的PDB液体培养基的配制方法如下:马铃薯200克、葡萄糖20克、琼脂20克、蛋白胨5克、磷酸二氢钾3克、硫酸镁1.5克溶于1000ml海水中配制而成;所述的PDA固体培养基的配制方法如下:马铃薯200克、葡萄糖20克、琼脂20克、蛋白胨5克、磷酸二氢钾3克、硫酸镁1.5克、琼脂粉18克溶于1000ml海水中配制而成。
5.根据权利要求2所述的一种七元环吲哚萜类化合物的制备方法,其特征在于步骤(3)所述的石油醚-乙酸乙酯溶液的洗脱梯度体积比依次为100:1、50:1、20:1、10:1、5:1、2:1、1:1和0:1。
6.根据权利要求2所述的一种七元环吲哚萜类化合物的制备方法,其特征在于:步骤(3)中所述的反相反相中压柱层析梯度洗脱中乙腈体积百分比从25~100%,洗脱时间200min。
7.根据权利要求2所述的一种七元环吲哚萜类化合物的制备方法,其特征在于:步骤(3)中所述的半制备反相高效液相色谱的化合物分离制备的流速为2.0mL/min。
8.一种权利要求1所述的七元环吲哚萜类化合物在制备白色念珠球菌抑制剂的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310019184.5A CN116535415A (zh) | 2023-01-06 | 2023-01-06 | 一种七元环吲哚萜类化合物及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310019184.5A CN116535415A (zh) | 2023-01-06 | 2023-01-06 | 一种七元环吲哚萜类化合物及其制备方法和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116535415A true CN116535415A (zh) | 2023-08-04 |
Family
ID=87447757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310019184.5A Pending CN116535415A (zh) | 2023-01-06 | 2023-01-06 | 一种七元环吲哚萜类化合物及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116535415A (zh) |
-
2023
- 2023-01-06 CN CN202310019184.5A patent/CN116535415A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113105428B (zh) | 一种氧杂蒽酮类化合物及其制备方法和用途 | |
CN110330544B (zh) | 一种4,4,1-双环甾类化合物及其制备方法和用途 | |
US11851692B2 (en) | Method for preparing an antimycin compound produced by Streptomyces sp.4-7 | |
CN110003153B (zh) | 一种苯并呋喃类化合物及其制备方法和用途 | |
CN111072670B (zh) | 一种二酮哌嗪类化合物及其制备方法和用途 | |
CN110862371B (zh) | 多环聚酮类化合物及其制备方法和在制备抗菌药物中的应用 | |
CN110357788B (zh) | 一种聚酮类化合物及其制备方法和用途 | |
CN108441427B (zh) | 一种节菱孢属真菌及其生产的吡啶酮生物碱类化合物 | |
CN114380764B (zh) | 一种噻唑啉铁载体类型化合物及其制备方法和用途 | |
CN107686817B (zh) | 一株阔苞菊内生真菌CYSK-4及其生产的Ascomylactam类化合物的应用 | |
CN107805188B (zh) | 一种联苯类化合物及其制备方法和用途 | |
CN113444131B (zh) | N-乙酰氨基葡萄糖类化合物及其制备方法和应用 | |
CN116535415A (zh) | 一种七元环吲哚萜类化合物及其制备方法和用途 | |
CN110002996B (zh) | 一种二苯醚类化合物及其制备方法和用途 | |
CN111748489B (zh) | 海洋灰平链霉菌hn60及其应用 | |
CN109912623B (zh) | 一种氧杂蒽酮类化合物、其制备方法和应用 | |
CN108794502B (zh) | 一种单端孢霉烯类化合物及其制备方法和用途 | |
CN110563740A (zh) | 一种ɑ-吡喃酮化合物、制备方法,菌株及应用 | |
CN116041165B (zh) | 一种倍半萜类化合物及其制备方法和用途 | |
CN117510451B (zh) | 一种苯骈吡喃二聚体轮层炭菌素及其制备方法和应用 | |
CN112694406B (zh) | 两种二聚己基衣康酸衍生物的制备方法和应用 | |
CN114702468B (zh) | 一种二氢苯并呋喃类化合物及其制备方法和用途 | |
CN113173904B (zh) | 新的抑菌化合物以及用于制备该化合物的曲霉 | |
CN114606135B (zh) | 一种海绵共附生真菌及其在制备甾醇类化合物中的应用 | |
CN114469908B (zh) | 一种抗鲍曼不动杆菌化合物stemphol的制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |